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Abstract
Background: Prenatal factors may contribute to the development of peanut allergy. We evaluated the risk of
childhood peanut allergy in association with pregnancy exposure to Rh immune globulin, folic acid and ingestion
of peanut-containing foods.
Methods: We conducted a web-based case-control survey using the Anaphylaxis Canada Registry, a pre-existing
database of persons with a history of anaphylaxis. A total of 1300 case children with reported peanut allergy were
compared to 113 control children with shellfish allergy. All were evaluated for maternal exposure in pregnancy to
Rh immune globulin and folic acid tablet supplements, as well as maternal avoidance of dietary peanut intake in
pregnancy.
Results: Receipt of Rh immune globulin in pregnancy was not associated with a higher risk of peanut allergy
(odds ratio [OR] 0.86, 95% confidence interval [CI] 0.51 to 1.45), nor was initiation of folic acid tablet supplements
before or after conception (OR 0.53, 95% CI 0.19 to 1.48). Complete avoidance of peanut-containing products in
pregnancy was associated with a non-significantly lower risk of peanut allergy (OR 0.53, 95% CI 0.27 to 1.03).
Conclusion: The risk of childhood peanut allergy was not modified by the following common maternal exposures
in pregnancy: Rh immune globulin, folic acid or peanut-containing foods.
Clinical implications: Rh immune globulin, folic acid supplement use and peanut avoidance in pregnancy have
yet to be proven to modulate the risk of childhood anaphylaxis to peanuts.
Capsule Summary: Identification of prenatal factors that contribute to peanut allergy might allow for prevention
of this life-threatening condition. This article explores the role of three such factors.
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Introduction
Prenatal and early life factors may contribute to the sub-
sequent development of allergic conditions in childhood
[1]. A better understanding and prevention of exposure
to such factors could theoretically lead to the rational
amelioration of some common and potentially life-threa-
tening allergic conditions. In this study, we focused on
three potentially important factors in the prenatal per-
iod: Rh immune globulin, folic acid supplements and
ingestion of peanut-containing foods.
Rh immune globulin is a blood derived product with
known immunomodulatory effects [2-4]. It is
administered to Rh-negative mothers at 28 weeks’ gesta-
tion to prevent alloimmunization to fetal Rh antigens, or
within 72 hours of an obstetrical delivery or pregnancy
termination. About 15% of Caucasian women, 4% to 8%
of women of African ancestry and less than 1% of Asian
women are Rh negative. Concerns about the use of Rh
immune globulin were raised by members of a patient
support group, who noted that several mothers of pea-
nut allergic children had received Rh immune globulin
during their pregnancy with the affected child.
Routine folic acid tablet supplementation in pregnancy
became widespread in the early 1990s. This roughly cor-
related with the period during which peanut allergy and
other allergic conditions became more prevalent [1].
Dietary methyl donors, including folic acid, can influ-
ence the expression of certain genes through DNA
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mechanisms have been postulated to play a role in the
development of allergic conditions [6]. Key genes
involved in the regulation of immune and allergic
responses, including Fox P3, are known to be affected
by methylation [7].
Concern has also been raised about the risk of child-
hood peanut allergy following ingestion during preg-
nancy and lactation [8]. This has led some to
recommend dietary avoidance of all peanut products
during pregnancy and lactation [9]. However, recent stu-
dies have questioned this approach, since the incidence
of peanut allergy may actually be higher following avoid-
ance of peanut products [1].
We explored the risk of childhood peanut allergy in
association with pregnancy exposure to Rh immune glo-
bulin, folic acid and peanut-containing foods using a
large Canadian database of children with a history of
anaphylaxis.
Methods
A retrospective web-based case-control study was com-
pleted using the Anaphylaxis Canada Registry. This reg-
istry is a pre-existing database comprising approximately
8,000 anaphylactic patients registered from across
Canada [[10], accessed 2008]. Members of Anaphylaxis
Canada form a group of highly motivated individuals
who are eager to participate in research on severe
allergy in children. Response rates to previous research
projects are typically over 85%.
All study participants were previously registered with
Anaphylaxis Canada, and have granted permission to Ana-
phylaxis Canada to contact them periodically with web-
based surveys. Our case group comprised parents or care-
givers of a child with a peanut allergy. The active control
group consisted of parents or caregivers of a child with a
non-peanut allergy, specifically a shellfish allergy. Those
with more than one child with an allergy were asked to
respond to details in regards to their first liveborn child.
For the current study, an email was sent out by Ana-
phylaxis Canada to all 2007 survey respondents of the
AC Member Survey 2007, all of whom previously stated
that they were a parent/guardian of a child with a life-
threatening allergy. Individuals were asked to respond to
additional questions for the current study (Appendix A).
Approval was granted by the Research Ethics Review
Board at Sunnybrook Health Sciences Centre, University
of Toronto, Toronto, Ontario, Canada. All participant
identifiers were removed from the dataset by Anaphy-
laxis Canada prior to its release to the investigators.
Statistical analysis
The risk of each exposure variable in pregnancy was
examined in association with case status of a peanut
allergy vs. control status of a shellfish allergy, and
expressed as an odds ratio (OR) and 95% confidence
interval (CI).
Results
A total of 1300 mothers of cases with peanut allergy and
113 mothers of controls with shellfish allergy completed
the current survey.
There were 812 (56.0%) mothers who reported they
were Rh-positive, 339 (23.8%) Rh negative and 276
(19.3%) who did not know their Rh blood type. Receipt
of Rh immune globulin in pregnancy was reported
among 19.1% of peanut allergy cases and 18.7% of shell-
fish allergy controls (OR 0.86, 95% CI 0.51 to 1.45)
(Table 1).
Initiation of folic acid tablet supplements before or
after conception, or throughout pregnancy (OR 0.53,
95% CI 0.19 to 1.48) was not associated with a signifi-
cantly different risk of peanut allergy (Table 1).
Complete reduction in intake of peanut-containing
products in pregnancy was associated with a non-signifi-
cantly lower risk of peanut allergy among cases (5.4%)
than controls (10.3%) (OR 0.53, 95% CI 0.27 to 1.03)
(Table 1).
Discussion
We evaluated three different antenatal maternal expo-
sure factors in association with childhood peanut allergy.
We did not detect an association with either Rh
immune globulin or antenatal folic acid tablet supple-
mentation and peanut allergy. Reduced ingestion of pea-
nut products in pregnancy was associated with a non-
significantly lower risk, however.
We chose to compare peanut-allergic children to
those will shellfish allergy, as peanut allergy generally
occurs early in life, whereas shellfish allergy often
occurs later in life. We therefore reasoned that prena-
tal or early life factors would be more likely to affect
the development of peanut as opposed to shellfish
allergy.
Strengths of our study are the large number of indi-
viduals surveyed through a large national database, as
well as its novelty. Study limitations include a guar-
dian-reported diagnosis of peanut or shellfish allergy in
the offspring, the unknown severity of such allergy, a
recall bias about the exposure risk factors assessed,
and incomplete responses to some questions. Folic
acid supplementation use was so widespread among
respondent mothers that it may have been difficult to
detect a true effect of folic acid supplementation
between cases and controls. While intentional dietary
peanut consumption in pregnancy was assessed, acci-
dental ingestion of trace amounts in food, or sensitiza-
tion via transcutaneous exposure was not. In addition,
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Page 2 of 5Table 1 Risk of peanut allergy vs. shellfish allergy in association with Rh immune globulin and folic acid exposure in pregnancy, as well as reduced intake of
peanut containing products in pregnancy
No. (%) with self-reported exposure
Maternal exposure in index pregnancy Among mothers of cases with a peanut
allergy
Among mothers of controls with a shellfish
allergy
Odds ratio
(95% CI),
cases vs.
controls
Received Rh immune globulin No (n = 1027) 961 (73.2) 66 (61.7) 1.00 (ref)
Yes (n = 271) 251 (19.1) 20 (18.7) 0.86
(0.51 to 1.45)
Unknown (n = 121) 100 (7.6) 21 (19.6) –
Initiated a folic acid supplement before conception No (n = 560) 508 (38.7) 52 (48.6) 1.00 (ref)
Yes (n = 817) 764 (58.2) 53 (49.5) 1.48
(0.99 to 2.20)
Unknown (n = 42) 40 (3.1) 2 (1.9) –
Initiated a folic acid supplement after conception No (n = 53) 49 (9.0) 4 (7.3) 1.00 (ref)
Yes (n = 536) 485 (88.7) 51 (92.7) 0.78
(0.27 to 2.24)
Unknown (n = 13) 13 (2.4) 0 (0.0) –
Took a folic acid supplement throughout pregnancy No (n = 91) 87 (7.1) 4 (3.9) 1.00 (ref)
Yes (n = 1232) 1134 (92.2) 98 (95.2) 0.53
(0.19 to 1.48)
Unknown (n = 10) 9 (0.73) 1 (0.97) –
Reduced intake of peanut-containing products in
pregnancy
None (n = 1095) 1013 (77.6) 82 (76.6) 1.00 (ref)
Somewhat (n = 236) 222 (17.0) 14 (13.1) 1.28
(0.72 to 2.30)
Completely (n = 82) 71 (5.4) 11 (10.3) 0.53
(0.27 to 1.03)
Unknown (n = 58) 52 (3.8) 6 (5.3) –
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5we did not record the demographic features of the
respondents, non-respondents and their children,
which may alter the internal and external validity of
our findings. The first factor studied was the adminis-
tration of intravenous Rh immune globulin to pregnant
women, an important immunomodulatory strategy
commonly used to prevent the development of alloim-
munization to fetal Rh antigens. The second factor stu-
died was use of antenatal folic acid supplements, which
has roughly paralleled the rise in allergic conditions
[11]. Folate supplies methyl groups can epigenetically
alter DNA and permanently affect gene expression
resulting in reduced expression of Fox P3 and develop-
ment of T regulatory cells [7]. This might predispose
to the development of allergy, as evidenced in animal
[12] and human studies [11]. Since both Rh immune
globulin and folic acid have demonstrated benefits,
future controlled studies would be difficult to conduct,
and their absence of an association with peanut allergy
may be reassuring to mothers.
The third factor studied – reduced maternal inges-
tion of peanut products – was associated with a non-
significantly lower risk of peanut allergy in the off-
spring. The observation that some children experience
allergic reactions to their first ingestion of peanut pro-
ducts suggests that sensitization may occur in utero,
leading to recommendations of avoidance of peanut
consumption during pregnancy and lactation [9]. How-
ever the risk of peanut allergy may be higher despite
avoidance of peanut ingestion [1], possibly due to
transcutaneous, rather than oral sensitization [13], a
factor not addressed in this study.
Further studies are needed to delineate the risk factors
that may contribute to the development of peanut
allergy.
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Appendix A
Allergy questionnaire
￿ The following questions only apply to the pregnancy
when you carried your eldest child with an allergy.
￿ Please answer each question as fully and accurately
as possible.
￿ Please only provide one response to each question.
￿ You may need to check with your doctor to answer
some of the questions, so take your time.
￿ Your responses will help us determine what factors
during pregnancy may or may not relate to the develop-
ment of an allergy in your child.
1. Did the mother of the current child with allergy
receive Rh immune globulin (RhoGAM) during that
pregnancy? (You may need to check with the person
who took care of you in your pregnancy, as this
information will be recorded in your prenatal chart)
Yes
No
Do not know
2. At the time that the child with allergy was con-
ceived (at the time that you actually became preg-
nant) was the mother of the child with allergy taking
a multivitamin supplement containing folic acid or a
folic acid supplement?
Yes
No
Do not know
3. If the mother of the child was NOT taking a mul-
tivitamin supplement containing folic acid or a folic
acid supplement at the time that the child was con-
ceived, did the mother start taking a supplement
one once she suspected or knew that she was
pregnant?
Yes
No
Do not know
4. During the above pregnancy, which of the follow-
ing best describes how much, if any, peanut or pea-
nut containing products the mother ate during
pregnancy?
I continued to eat peanut containing products
without any special restrictions.
I ate fewer peanut containing products than
usual, but I did not go out of my way to avoid
them (for example, I did not specifically read
food labels to make sure that they were free of
small amounts of peanut product; OR, I know
that I ate some peanut products during preg-
nancy, but not very often).
I was very careful to completely avoid peanut
containing products during pregnancy, and, as
far as I know, I did not consume any.
Other (please explain)
5. After the above pregnancy, which of the following
best describes how much, if any, peanut or peanut
containing products the mother ate during
breastfeeding?
I continued to eat peanut containing products
without any special restrictions.
I ate fewer peanut containing products than
usual, but I did not go out of my way to avoid
them (for example, I did not specifically read
food labels to make sure that they were free of
small amounts of peanut product; OR, I know
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nancy, but not very often).
I was very careful to completely avoid peanut
containing products during pregnancy, and, as
far as I know, I did not consume any.
I did not breastfeed
Abbreviations
CI: confidence interval; DNA: deoxyribonucleic acid; OR: odds ratio.
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